Next Generation Multiresponsive Nanocarriers for Targeted Drug Delivery to Cancer Cells. Issue 41 (19th August 2016)

• Record Type: Journal Article
• Authors: Altenbuchner, Peter T.; Werz, Patrick D. L.; Schöppner, Patricia; Adams, Friederike; Kronast, Alexander; Schwarzenböck, Christina; Pöthig, Alexander; Jandl, Christian; Haslbeck, Martin; Rieger, Bernhard
• Is Part Of: Chemistry. Volume 22:Issue 41(2016)
• Page Start: 14576
• Page End: 14584
• Publication Date: 2016-08-19
• Subjects: drug delivery -- group-transfer polymerization -- micelles -- stimuli-responsive release -- vinylphosphonates; Chemistry -- Periodicals; 540
• DOI: 10.1002/chem.201601822
• Languages: English
• ISSNs: 0947-6539

Abstract

Abstract: C−H bond activation of 2‐methoxyethylamino‐bis(phenolate)‐yttrium catalysts allowed the synthesis of BAB block copolymers comprised of 2‐vinylpyridine (2VP; monomer A) and diethylvinylphosphonate (DEVP; monomer B) as the A and B blocks, respectively, by rare‐earth‐metal‐mediated group‐transfer polymerization (REM‐GTP). The inherent multi‐stimuli‐responsive character and drug‐loading and ‐release capabilities were observed to be dependent on the chain length and monomer ratios. Cytotoxicity assays revealed the biocompatibility and nontoxic nature of the obtained micelles toward ovarian cancer (HeLa) cells. The BAB block copolymers effectively encapsulated, transported, and released doxorubicin (DOX) within HeLa cells. REM‐GTP enables access to previously unattainable vinylphosphonate copolymer structures, and thereby unlocks their full potential as nanocarriers for stimuli‐responsive drug delivery in HeLa cells. The self‐evident consequence is the application of these new micelles as potent drug‐delivery vehicles with reduced side effects in future cancer therapies. Abstract : Multiresponsive BAB block copolymers based on 2‐vinylpyridine and vinylphosphonates were synthesized by rare‐earth‐metal‐mediated group‐transfer polymerization (REM‐GTP, see figure). Drug‐loading‐capability experiments with doxorubicin (DOX) and ovarian cancer (HeLa) cells demonstrated the biocompatibility of the vinylphosphonate carriers.